Evolus (EOLS) Q1 2026 earnings review
Profitability Reached, But Flagship Toxin Revenue Shrinks
Evolus successfully printed its second consecutive quarter of profitability, delivering $0.6M in Adjusted EBITDA during its seasonally weakest quarter. However, beneath the 7% YoY total revenue growth lies a troubling metric: the legacy toxin business (Jeuveau/Nuceiva) revenue actually shrank YoY, meaning top-line growth was entirely dependent on the new Evolysse filler franchise. Looming overhead is a newly announced 15% U.S. tariff on South Korean pharmaceuticals starting September 2026, which fundamentally threatens the company's gross margin structure just as operational leverage begins to take hold.
🐂 Bull Case
Management's structural cost reductions from mid-2025 are paying off. Non-GAAP operating expenses dropped sequentially from $53.0M in 25Q4 to $49.1M in 26Q1, allowing the company to squeeze out an Adjusted EBITDA profit in a seasonally light revenue quarter.
Evolus Rewards continues to be a formidable moat, growing to nearly 1.5 million members (+27% YoY) with an all-time high of 255,000 quarterly redemptions. A 71% customer reorder rate indicates strong retention.
🐻 Bear Case
While total revenue grew 7% YoY, Toxin revenue fell from $68.1M in 25Q1 to $66.4M in 26Q1 (-2.4%). Management claimed Jeuveau 'unit growth,' which implies severe pricing pressure, negative mix shift, or heavy promotional discounting is masking the revenue contraction.
A recently announced 15% U.S. tariff on patented pharmaceuticals from South Korea goes into effect on Sept 29, 2026. Because Jeuveau represents ~90% of total revenue, this poses a devastating threat to gross margins if pricing power remains weak.
⚖️ Verdict: 🔴
Bearish. Generating positive EBITDA is a major milestone, but the underlying quality of the revenue growth is poor. With the flagship product shrinking YoY and a 15% structural cost increase looming in late 2026, the path to the 2028 margin targets looks increasingly fraught.
Key Themes
Jeuveau Revenue Contraction Contradicts Positive Narrative
Management stated that 'underlying demand across the business remains healthy' and cited Jeuveau unit growth. However, manual calculation reveals Toxin revenue declined 2.4% YoY ($66.4M vs $68.1M in 25Q1). Total company growth was mathematically entirely reliant on the $6.7M from the Evolysse HA gels (which had not yet launched in 25Q1). This discrepancy points to heavy discounting or unfavorable international mix dragging down price realization.
Looming Macro Threat: South Korean Tariffs
The White House announced a 15% tariff on patented pharmaceuticals from South Korea, effective September 29, 2026. This hits Evolus directly at its core supplier (Daewoong). Management notes the 3-year shelf life of Jeuveau allows for pre-buying mitigation, but this is merely a temporary delay to a structural margin degradation, especially since the company already struggles with pricing power.
Structural OpEx Discipline Unlocks Profitability
The company's sharp pivot toward profitability in mid-2025 continues to pay dividends. Non-GAAP operating expenses dropped sequentially to $49.1M in 26Q1 (down from $53.0M in 25Q4). This discipline allowed Evolus to post an Adjusted EBITDA of $0.6M in a historically weak quarter, validating the leverage potential of their commercial platform.
Evolysse Sequential Growth is Stalling
The HA Gel franchise generated $6.7M in 26Q1. This is a decelerating trend sequentially from $7.2M in 25Q4, and far below the $9.7M recorded during the Q2 2025 launch. To hit the 2026 guidance of 10-12% of total revenue ($33M+), the filler franchise must abruptly accelerate to average nearly $9M per quarter for the rest of the year.
European Expansion: Estyme Launch Approaching
A key upcoming catalyst is the mid-May 2026 commercial launch of all four injectable hyaluronic acid gels under the Estyme brand in Europe. With U.S. filler demand acting sluggish, geographic diversification is critical to hitting the ambitious 2028 revenue targets.
Loyalty Program Creates High Stickiness
The Evolus Rewards program is a highly effective moat. Reaching roughly 1.5 million members (up 27% YoY), it drives a 70% repeat treatment rate independent of broader macroeconomic weakness. Over 18,100 customers have purchased from Evolus since inception, pushing U.S. account penetration above 60%.
Other KPIs
Accelerating/Improving from -$15.6M in the prior year period. The cash burn continues but is shrinking as the company dials back expenses. The balance sheet remains sufficiently capitalized with $49.8M in cash, backed by an additional $120M in debt capacity.
Decelerating YoY from 69.2% in 25Q1, though improving sequentially from 66.6% in 25Q4. The drag is attributed to a rising mix of Evolysse (which currently absorbs a 10% EU tariff) and introductory pricing programs.
Guidance
Accelerating mathematically. This implies 10% to 13% YoY growth. Since Q1 printed just 7% growth, the company must execute substantial acceleration in Q2-Q4. Management explicitly expects 'high single-digit Jeuveau growth in the first half and supporting double-digit total revenue growth for the full year', indicating a back-half weighted recovery.
Stable. Represents 0% to 3% growth over 2025 levels, demonstrating extreme fiscal discipline. This cost control is the primary mechanism supporting the guided 'low- to mid-single digit Adjusted EBITDA margin' for 2026.
Accelerating. Translates to roughly $33M to $40M for the year. Given Q1 delivered only $6.7M, significant acceleration is required, placing heavy execution risk on the upcoming Estyme launch in Europe.
Key Questions
Jeuveau Pricing Dynamics
You highlighted Jeuveau unit growth in Q1, but Toxin revenue mathematically declined year-over-year. How much of this was driven by aggressive pricing or portfolio rebate programs, and when do you expect price realization to stabilize?
Tariff Mitigation Reality Check
Regarding the 15% South Korean tariff beginning in September 2026, leveraging the 3-year shelf life is a temporary inventory solution. What are the long-term structural fixes—manufacturing relocation, aggressive price hikes, or supplier concessions—to prevent this from permanently crushing gross margins in 2027?
Evolysse Sequential Plateau
Evolysse revenue declined sequentially from Q4 to Q1 ($7.2M down to $6.7M). What gives you confidence in the steep acceleration required in the next three quarters to meet the 10-12% full-year contribution guidance?